Abstract When Furchgott, Murad, and Ignarro were honored with the Nobel prize for the
identification of nitric oxide (NO) in 1998, the therapeutic implications of this discovery could …

Nitric oxide (NO) signaling represents one of the major regulatory pathways for
cardiovascular function. After the discovery of NO, awarded with the Nobel Prize in 1998 …

The vasodilatory properties of nitric oxide (NO) have been utilized in pharmacotherapy for
more than 130 years. Still today, NO‐donor drugs are important in the management of …

Soluble guanylate cyclase (sGC) is a key enzyme in the nitric oxide (NO) signalling pathway.
On binding of NO to its prosthetic haem group, sGC catalyses the synthesis of the second …

Oxidative stress, a risk factor for several cardiovascular disorders, interferes with the
NO/sGC/cGMP signalling pathway through scavenging of NO and formation of the strong …

Soluble guanylyl cyclase (sGC) is the only proven receptor for the ubiquitous biological
messenger nitric oxide (NO) and is intimately involved in many signal transduction …

Soluble guanylate cyclase (sGC), a key enzyme of the nitric oxide (NO) signaling pathway, is
attracting rapidly growing interest as a therapeutic target in cardiopulmonary disease, with …

Direct stimulation of soluble guanylate cyclase (sGC) represents a promising therapeutic
strategy for the treatment of a range of diseases, including the severely disabling pulmonary …

Soluble guanylate cyclase (sGC) is a key signal-transduction enzyme activated by nitric
oxide (NO). Impaired bioavailability and/or responsiveness to endogenous NO has been …

It is now well established that the NO-sGC-cGMP signal transduction system mediates many
different physiological functions in almost every conceivable organ system; this has been …